Posted Nov. 15, 2011 at 10:30 a.m.

Premium Lock Salix faces tough questions from FDA about expanded use of drug

Published: 2011-11-15 10:30:03
Updated: 2011-11-15 10:30:03

Salix Salix

Salix is preparing for new set of Xifaxan phase 3 clinical trials studying the irritable bowel syndrome indication, which puts approval about two years away. But first the company will meet with an FDA advisory panel on Wednesday, eight months after receiving the complete response letter from the agency declining approval on Xifaxan as a new IBS treatment....

Read More
Read More

Copyright 2017 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders